IGS05

IGS05 is an investigational drug candidate currently in the pre-clinical stage of development by Ignis Therapeutics. It is being developed for the treatment of Treatment-Resistant Depression (TRD) and synaptopathies, a group of neurological disorders characterized by synaptic dysfunction. While the specific molecular target and mechanism of action have not been publicly disclosed, the program is part of Ignis Therapeutics' CNS-focused pipeline, which primarily utilizes small molecule modalities to address unmet needs in neuropsychiatry and neurology. The development of IGS05 aims to provide new therapeutic options for patients who do not achieve adequate relief from standard antidepressant treatments.